Brexit: What next for the pharmaceutical and life sciences sector?

Brexit is the most significant upset to the European order since the European Economic Community was founded in 1957, casting waves of of constitutional, political and economic impacts that will be seen for years to come. Both sides of the table are working tirelessly to arrive at agreements on the withdrawal, transition and future trading relationship. Some progress is being made, though by no means is any part of the agreement assured. Whether we end up with a customs partnership or without, businesses can expect a sleuth of changes which need to be anticipated and mitigated. This is especially true for highly regulated industries such as the Pharmaceutical and Life Sciences industry.

In this series of articles we will explore some of the potential changes that can be expected across different functional areas.


{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}

Contact us

Jo Pisani

Pharmaceutical and Life Science Consulting Leader, PwC United Kingdom

Tel: +44 (0)7736 599749

Jules Kirby

Director, PwC United Kingdom

Tel: +44 (0) 7703 563 662

Follow us